ClinicalTrials.gg
CompletedNCT00318643Updated Oct 29, 2021Results posted

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

A Phase 1/2 interventional study of Mitomycin C and Chemophase in Bladder Cancer, sponsored by Halozyme Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Halozyme Therapeutics · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing mitomycin in Urinary Bladder Neoplasms — 5 open to participants now, 10 under way, 2 of them phase 3. Mitomycin · Urinary Bladder Neoplasms.

Enrollment
20th of 26
27 · median 61
Started
2006
the only one that year
Phase 1/2
2 of 26
1 open now
Registered
3rd of 26
by date
Lead sponsor
1 of 26
Halozyme Therapeutics

Among the 26 studies testing mitomycin in Urinary Bladder Neoplasms, this one is the 20th largest by enrollment, is the only one that started in 2006, is one of 2 in phase 1/2, and was the 3rd registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

5 of the 26 studies testing mitomycin in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mitomycin

Mitomycin: first FDA approval 1981 (MUTAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing mitomycin in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to explore a treatment that potentially enhances the delivery of chemotherapy to tumors in participants with superficial bladder cancer. The investigational medication to be studied is an enzyme called ChemophaseTM (recombinant human hyaluronidase, rHuPH20). Chemophase is being specifically developed for use with other anticancer drug to increase the local penetration of the anticancer drug for the treatment of superficial bladder cancer. In this study, Chemophase will be given in combination with mitomycin C directly into the bladder. Mitomycin C is an anti-tumor drug that is commonly used to treat superficial bladder cancer. It is envisioned that Chemophase with mitomycin C may potentially increase the local penetration of mitomycin C into remaining cancer cells following surgery to treat superficial bladder cancer.

Read the detailed description

The primary objectives of this study are to:

  1. determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin (mitomycin C, MMC) administered as weekly intravesical instillations for five weeks, and
  2. establish the dose of Chemophase with MMC recommended for future studies.

The secondary objectives of this study are to:

  1. assess the pharmacokinetics of intravesical administration of MMC alone and in combination with intravesical administration of Chemophase,
  2. for those participants treated at the MTD, assess the safety and tolerability of intravesical administration of MMC with Chemophase over up to 7 additional maintenance treatments every 3 months following the initial six weekly instillations, and
  3. observe participants for any preliminary evidence of anti-tumor activity of MMC and Chemophase when combined.

Study participants will receive six weekly study treatments administered intravesically (at Weeks 1 through 6) followed by post-treatment evaluations, at Weeks 8 and 12. The 12 participants treated at MTD will continue to receive combination therapy every three months until the end of Year 2 or until the time of documented tumor recurrence, whichever occurs first. For other participants, long-term follow-up after Week 12 will consist of disease monitoring of participants by telephone and will be performed every three months beginning three months after last study treatment for two years and then every six months thereafter, until bladder tumor recurrence.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Non-invasive bladder cancer
  • Chemophase
  • Intravesical administration
  • Superficial Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with initial presentation or recurrence of Stage Ta, T1 or Tis, any grade, bladder cancer after transurethral resection of bladder tumor (TURBT).
  • TURBT within 42 days prior to Day 1/Week 1
  • Performance Status greater than or equal to 80%
  • at least 3 years
  • 18 years or older
  • A negative pregnancy test (if female of )
  • Acceptable liver function within 7 days defined as: less than or equal to 1.5 times , and (AST) Glutamic-oxalacetic transaminase (SGOT), alanine aminotransferase (ALT), glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase \<= 2.5 times upper limit of normal
  • Acceptable renal function within 7 days defined as: serum creatinine less than or equal to 1.5 times upper limit of normal, or calculated greater than or equal to 40 milliliter (mL)/minute/1.73 meter\^2
  • Acceptable hematologic status within 7 days defined as: (ANC) greater than or equal to 2,500 cells/millimeter\^3, count greater than or equal to 150,000/millileter\^3, and greater than or equal to 10.0 grams/deciliter.
  • Urinalysis showing no abnormalities except those attributable to bladder cancer.
  • For men and women of child-producing potential, agreement to use an effective method during the treatment period of the study.
  • Signed, written Institutional Review Board (IRB)-approved

Exclusion criteria

Exclusion Criteria:

  • History or previous diagnosis of bladder fibrosis
  • Total bladder capacity estimated at cystoscopy to be less than 150 mL
  • Urinary incontinence of a severity that would compromise the ability of the participant to retain the study drug intravesical instillation for two hours.
  • Severe irritative voiding symptoms such as urgency, frequency, or nocturia
  • Known other malignant disease except squamous or basal cell skin cancer unless the has been in complete remission off therapy for at least 5 years.
  • Major surgery, other than TURBT and diagnostic surgery, within 28 days prior to Day 1/Week 1.
  • Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection.
  • Treatment with radiation therapy, surgery, chemotherapy, or therapy within one month prior to Day 1/Week 1 on study (two months for nitrosureas or MMC), unless given as standard treatment for bladder cancer and provided that patient is free of all treatment-related toxicities as of Day 1/Week 1.
  • Known infection with (HIV)
  • Known active infection with or
  • Serious disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor (Halozyme).
  • History of a or idiosyncratic reaction to, or other to, mitomycin.
  • Known allergy to bee or vespid venom
  • Known coagulation disorder or bleeding tendency
  • Treatment with heparin or anticipation of heparin treatment during the treatment period in this study.
  • Unwillingness or inability to comply with procedures required in this protocol.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort 1: MMC plus Chemophase 20,000 U

    Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.

    Drug: Mitomycin C · Drug: Chemophase

  • Experimental
    Cohort 2: MMC plus Chemophase 60,000 U

    Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.

    Drug: Mitomycin C · Drug: Chemophase

  • Experimental
    Cohort 3: MMC plus Chemophase 200,000 U

    Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.

    Drug: Mitomycin C · Drug: Chemophase

  • Experimental
    Cohort 4: MMC plus Chemophase 400,000 U

    Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.

    Drug: Mitomycin C · Drug: Chemophase

  • Experimental
    Cohort 5: MMC plus Chemophase 800,000 U

    Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.

    Drug: Mitomycin C · Drug: Chemophase

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC

    The MTD was defined as the maximum dose level at which no more than two of six participants experienced dose-limiting toxicities (DLT). DLT was defined as any of the following: * Plasma MMC concentration greater than or equal to (\>=) 100 nanograms (ng)/milliliter (mL) * Adverse event (AE) with a Common Toxicity Criteria (CTC) grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.

    Time frame: 5 weeks (Week 2 to Week 6)

  2. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT was defined as any of the following: * Plasma MMC concentration \>= 100 ng/mL * AE with a CTC grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.

    Time frame: 5 weeks (Week 2 to Week 6)

  3. Recommended Dose of Chemophase With MMC For Future Studies

    Time frame: 5 weeks (Week 2 to Week 6)

Secondary outcomes

  1. Number of Participants With a Quantifiable MMC Plasma Concentration Value

    A quantifiable MMC plasma concentration value was a value that was not below the quantifiable limit (BQL) of \<10.0 nanogram/milliliter (ng/mL).

    Time frame: 0 (predose), 1, 2, and 3 hours postdose at Weeks 1, 2, 5, and 6

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAEs were defined as any AE that occurred after the first administration of the study drug and until the end of the study. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.

    Time frame: Baseline up to 2 years

  3. Number of Participants Who Remained Tumor Free at the End of the Study

    Time frame: Baseline up to 2 years

07

Results

Posted Oct 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
Started336312
Received at least 1 dose of study drug336312
Completed33639
Not completed00003
Withdrew: Adverse event00001
Withdrew: Participant's decision00001
Withdrew: Investigator's decision00001

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Chemophase in Combination With MMC

The MTD was defined as the maximum dose level at which no more than two of six participants experienced dose-limiting toxicities (DLT). DLT was defined as any of the following: * Plasma MMC concentration greater than or equal to (\>=) 100 nanograms (ng)/milliliter (mL) * Adverse event (AE) with a Common Toxicity Criteria (CTC) grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.

Time frame:
5 weeks (Week 2 to Week 6)
Reported as:
Number · Units
Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC
UnitsCohort 5: MMC Plus Chemophase 800,000 U
Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC800000
PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLT was defined as any of the following: * Plasma MMC concentration \>= 100 ng/mL * AE with a CTC grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.

Time frame:
5 weeks (Week 2 to Week 6)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
Number of Participants With Dose Limiting Toxicities (DLTs)00100
PrimaryRecommended Dose of Chemophase With MMC For Future Studies
Time frame:
5 weeks (Week 2 to Week 6)
Reported as:
Number · Units
Recommended Dose of Chemophase With MMC For Future Studies
UnitsCohort 5: MMC Plus Chemophase 800,000 U
Recommended Dose of Chemophase With MMC For Future Studies800000
SecondaryNumber of Participants With a Quantifiable MMC Plasma Concentration Value

A quantifiable MMC plasma concentration value was a value that was not below the quantifiable limit (BQL) of \<10.0 nanogram/milliliter (ng/mL).

Time frame:
0 (predose), 1, 2, and 3 hours postdose at Weeks 1, 2, 5, and 6
Reported as:
Count of participants · Participants
Number of Participants With a Quantifiable MMC Plasma Concentration Value
ParticipantsCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
Week 1: Predose00000
Week 1: 1 hour00001
Week 1: 2 hours00001
Week 1: 3 hours00000
Week 2: Predose00000
Week 2: 1 hour00000
Week 2: 2 hours00000
Week 2: 3 hours00000
Week 5: Predose00000
Week 5: 1 hour00000
Week 5: 2 hours00100
Week 5: 3 hours00100
Week 6: Predose00000
Week 6: 1 hour00010
Week 6: 2 hours00010
Week 6: 3 hours00000
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAEs were defined as any AE that occurred after the first administration of the study drug and until the end of the study. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.

Time frame:
Baseline up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
TEAEs114210
SAEs10202
SecondaryNumber of Participants Who Remained Tumor Free at the End of the Study
Time frame:
Baseline up to 2 years
Reported as:
Count of participants · Participants
Number of Participants Who Remained Tumor Free at the End of the Study
ParticipantsCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
Number of Participants Who Remained Tumor Free at the End of the Study20216

Adverse events

Collected over Baseline up to 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: MMC Plus Chemophase 20,000 U—1/3 (33.3%)0/3 (0%)
Cohort 2: MMC Plus Chemophase 60,000 U—0/3 (0%)1/3 (33.3%)
Cohort 3: MMC Plus Chemophase 200,000 U—2/6 (33.3%)4/6 (66.7%)
Cohort 4: MMC Plus Chemophase 400,000 U—0/3 (0%)2/3 (66.7%)
Cohort 5: MMC Plus Chemophase 800,000 U—2/12 (16.7%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
SyncopeNervous system disorders1/30/30/60/30/12
NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/31/60/30/12
Small cell lung cancer stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/31/60/30/12
Gastrointestinal haemorrhageGastrointestinal disorders0/30/31/60/30/12
Chest painGeneral disorders0/30/31/60/30/12
PneumoniaInfections and infestations0/30/30/60/31/12
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/60/31/12
Acute myocardial infarctionCardiac disorders0/30/30/60/31/12
Angina unstableCardiac disorders0/30/30/60/31/12
Most frequent other events
Showing 10 of 51
Most frequent other events
EventCohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 U
Urinary tract infectionInfections and infestations0/31/32/60/32/12
CellulitisInfections and infestations0/31/30/60/30/12
Cerebral ischaemiaNervous system disorders0/31/30/60/30/12
Red blood cells urine positiveInvestigations0/30/31/61/30/12
White blood cells urine positiveInvestigations0/30/31/61/30/12
Blood urine presentInvestigations0/30/30/61/30/12
White blood cells urineInvestigations0/30/30/61/30/12
Asymptomatic bacteriuriaInfections and infestations0/30/31/60/30/12
NasopharyngitisInfections and infestations0/30/31/60/30/12
HeadacheNervous system disorders0/30/31/60/30/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 UTotal
Mean66.7 ± 11.2467.0 ± 8.5465.7 ± 10.3373.7 ± 3.7968.0 ± 10.5467.9 ± 9.44
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: MMC Plus Chemophase 20,000 UCohort 2: MMC Plus Chemophase 60,000 UCohort 3: MMC Plus Chemophase 200,000 UCohort 4: MMC Plus Chemophase 400,000 UCohort 5: MMC Plus Chemophase 800,000 UTotal
Female022037
Male3143920
08

Study locations

5 sites
  • BCG Oncology
    Phoenix, Arizona 85032, United States
  • MedResearch
    La Mesa, California 91942, United States
  • Malcolm Randall Veterans Administration Urology Section (112-C)
    Gainesville, Florida 32608, United States
  • Advanced Research Institute
    New Port Richey, Florida 34652, United States
  • James A. Haley Veterans Hospital
    Tampa, Florida 33612, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2006 to primary completion in Aug 2009, 40 months.

Results were first posted in Oct 2021, 12 years 2 months after primary completion. A results delay was requested in Aug 2018.

Of 39 industry-sponsored phase 1/2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 74. This study's 40 months is below that.

Counting every sponsor, half of 67 studies reached it within 52 months; a quarter within 35 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2006
First posted
Apr 27, 2006
StartActual
Mar 30, 2006
Primary completionActual
Aug 11, 2009
CompletionActual
Aug 11, 2009
Results delay requested
Aug 13, 2018
Results first posted
Oct 29, 2021
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00318643
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Mar 30, 2006
Primary completion
Aug 11, 2009
Completion
Aug 11, 2009
Results posted
Oct 29, 2021
Last update
Oct 29, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mitomycin · Hyaluronidase (human recombinant)

Start the discussion